Therapy
Anifrolumab
Human IgG1κ anti-IFNAR1 mAb: blocks ALL type I interferons (IFN-α, IFN-β, IFN-ω) simultaneously by targeting receptor subunit 1.
Also called: Saphnelo, anti-IFNAR, type I IFN blockade
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 2 and is affected by 2 concepts — mostly 1 receptor, 1 disease, 1 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
TULIP-2 (N=362): BICLA 47.8% vs 31.5% placebo; TULIP-1 (missed primary endpoint due to endpoint selection issue, different composite); ISG15+ macrophage exclusive to Class III/IV LN (AI discovery explains why anifrolumab may have differential LN class efficacy).
Its connections at a glance
Each dot is a concept directly linked to Anifrolumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I015 · concept status: established. Select any connection above to inspect evidence for that specific link.